Tumor cell hypoxia and the hypoxia-response signaling system as a target for prostate cancer therapy

被引:9
作者
Anastasiadis, AG
Bemis, DL
Stisser, BC
Salomon, L
Ghafar, MA
Buttyan, R
机构
[1] Columbia Univ Coll Phys & Surg, Mol Urol Lab, Dept Urol, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Mol Urol Lab, Dept Pathol, New York, NY 10032 USA
关键词
prostate cancer; hypoxia; hypoxia inducible factor-1 alpha (HIF-1 alpha) angiogenesis; VEGF; apoptosis; Akt/protein kinase B;
D O I
10.2174/1389450033491136
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The accumulation of cancerous cells within a growing prostate tumor can deprive them of adequate vascular support. Without this support, the affected tumor cells become hypoxic, a condition that is usually unfavorable for the further growth and survival of eukaryotic cells. Mammalian cells, however, have the ability of responding to a hypoxic environment by activating a "hypoxia-response" signaling system. Ultimately, this signaling system upregulates the expression of a network of gene products that increase the propensity of the cell to survive even in this adverse environment. With increasing evidence that hypoxia and an activated hypoxia-response signaling system can influence progression (via increased angiogenic propensity and apoptotic resistance) and the therapeutic responsiveness of prostate cancer cells, this review will examine the concept of targeting hypoxia or the hypoxia-response system of prostate tumor cells as a means to suppress prostate tumor progression and metastasis or perhaps even as a means for eliminating prostate tumors in advanced prostate cancer patients.
引用
收藏
页码:191 / 196
页数:6
相关论文
共 54 条
[11]   Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer [J].
Cvetkovic, D ;
Movsas, B ;
Dicker, AP ;
Hanlon, AL ;
Greenberg, RE ;
Chapman, JD ;
Hanks, GE ;
Tricoli, JV .
UROLOGY, 2001, 57 (04) :821-825
[12]  
de Groot FMH, 2001, CURR MED CHEM, V8, P1093
[13]  
Denny W A, 2000, Lancet Oncol, V1, P25, DOI 10.1016/S1470-2045(00)00006-1
[14]   ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31
[15]   Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: A possible promotion mechanism of carcinogenesis [J].
Garayoa, M ;
Martínez, A ;
Lee, SM ;
Pío, R ;
An, WG ;
Neckers, L ;
Trepel, J ;
Montuenga, LM ;
Ryan, H ;
Johnson, R ;
Gassmann, M ;
Cuttitta, F .
MOLECULAR ENDOCRINOLOGY, 2000, 14 (06) :848-862
[16]  
GHAFAR MA, 2002, IN PRESS PROSTATE
[17]   Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway [J].
Huang, LE ;
Gu, J ;
Schau, M ;
Bunn, HF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) :7987-7992
[18]   Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1α [J].
Hur, E ;
Chang, KY ;
Lee, E ;
Lee, SK ;
Park, H .
MOLECULAR PHARMACOLOGY, 2001, 59 (05) :1216-1224
[19]   HIFα targeted for VHL-mediated destruction by proline hydroxylation:: Implications for O2 sensing [J].
Ivan, M ;
Kondo, K ;
Yang, HF ;
Kim, W ;
Valiando, J ;
Ohh, M ;
Salic, A ;
Asara, JM ;
Lane, WS ;
Kaelin, WG .
SCIENCE, 2001, 292 (5516) :464-468
[20]   Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation [J].
Jaakkola, P ;
Mole, DR ;
Tian, YM ;
Wilson, MI ;
Gielbert, J ;
Gaskell, SJ ;
von Kriegsheim, A ;
Hebestreit, HF ;
Mukherji, M ;
Schofield, CJ ;
Maxwell, PH ;
Pugh, CW ;
Ratcliffe, PJ .
SCIENCE, 2001, 292 (5516) :468-472